Human dialysable leucocyte extracts (transfer factor) in interstitial pneumonia. A retrospective trial in immunodeficient patients.
Thirty-six cases of interstitial pneumonia in acquired immunodeficient states were treated with transfer factor (Dialysable Leukocyte Extract) and studied retrospectively. The criteria of efficacity of this treatment were: rapidity of immediate improvement, improvement after failure of other immunostimulant therapy and demonstration of a dose-related effect. The mechanism of the therapeutic action is unclear. There is no evidence in favour of "transfer" of cell mediated immunity. A non-specific mode of action (adjuvant effect, interferon synergy, proinflammatory action) seems much more likely.
D002644:Chickenpox / Q000150:complications; D002648:Child; D002675:Child, Preschool; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000209:etiology / Q000276:immunology; D008457:Measles / Q000150:complications; D009748:Nutrition Disorders / Q000150:complications; D011379:Prognosis; D011658:Pulmonary Fibrosis / Q000150:complications / Q000188:drug therapy*; D014165:Transfer Factor / Q000627:therapeutic use*
D014165:Transfer Factor